NO311215B1 - Benzodiazepinderivater egnet til bruk som CCK- reseptorantagonister - Google Patents
Benzodiazepinderivater egnet til bruk som CCK- reseptorantagonister Download PDFInfo
- Publication number
- NO311215B1 NO311215B1 NO19943133A NO943133A NO311215B1 NO 311215 B1 NO311215 B1 NO 311215B1 NO 19943133 A NO19943133 A NO 19943133A NO 943133 A NO943133 A NO 943133A NO 311215 B1 NO311215 B1 NO 311215B1
- Authority
- NO
- Norway
- Prior art keywords
- benzodiazepine
- dihydro
- oxo
- urea
- phenyl
- Prior art date
Links
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title claims abstract description 4
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title abstract description 8
- 229940122623 CCK receptor antagonist Drugs 0.000 title 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 claims abstract description 20
- 102100036016 Gastrin/cholecystokinin type B receptor Human genes 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 12
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 211
- 150000001875 compounds Chemical class 0.000 claims description 158
- 239000004202 carbamide Substances 0.000 claims description 118
- 239000000203 mixture Substances 0.000 claims description 93
- -1 NHCHO where c is 0-2 Chemical group 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 150000001557 benzodiazepines Chemical class 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- WQULYWDOIINWGJ-UHFFFAOYSA-N 1-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 WQULYWDOIINWGJ-UHFFFAOYSA-N 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical group 0.000 claims description 9
- 102100021022 Gastrin Human genes 0.000 claims description 8
- 108010052343 Gastrins Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- MAXKXPNYSHCJHW-SANMLTNESA-N 1-[(3r)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea Chemical compound CNC1=CC=CC(NC(=O)N[C@H]2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 MAXKXPNYSHCJHW-SANMLTNESA-N 0.000 claims description 5
- FSFFUAFLXQLAQX-UHFFFAOYSA-N 1-[3-(dimethylamino)phenyl]-3-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound CN(C)C1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 FSFFUAFLXQLAQX-UHFFFAOYSA-N 0.000 claims description 5
- WFNOPNJYCVFERE-UHFFFAOYSA-N 3-[[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]carbamoylamino]benzoic acid Chemical compound O=C1N(CC(=O)C(C)(C)C)C2=CC=CC=C2C(C=2C=CC=CC=2)=NC1NC(=O)NC1=CC=CC(C(O)=O)=C1 WFNOPNJYCVFERE-UHFFFAOYSA-N 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 230000035790 physiological processes and functions Effects 0.000 claims description 5
- QGOXRTGPIJTFEY-UHFFFAOYSA-N 1-[1-(2-cyclopentyl-2-hydroxyethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(O)C3CCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 QGOXRTGPIJTFEY-UHFFFAOYSA-N 0.000 claims description 4
- GABUALDOFIACFO-UHFFFAOYSA-N 1-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3h-1,4-benzodiazepin-3-yl]-3-[3-[ethyl(methyl)amino]phenyl]urea Chemical compound CCN(C)C1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3N=CC=CC=3)=N2)=O)=C1 GABUALDOFIACFO-UHFFFAOYSA-N 0.000 claims description 4
- BLLORHYVWFCDES-UHFFFAOYSA-N 1-[1-(3,3-dimethyl-2-oxobutyl)-5-(4-methylphenyl)-2-oxo-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound C1=CC(C)=CC=C1C(C1=CC=CC=C1N(CC(=O)C(C)(C)C)C1=O)=NC1NC(=O)NC1=CC=CC(C)=C1 BLLORHYVWFCDES-UHFFFAOYSA-N 0.000 claims description 4
- VOPNRSWFTFKUAX-QUWDGAPNSA-N 1-[1-[2-[(2s)-1-acetylpyrrolidin-2-yl]-2-oxoethyl]-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC(=O)N1CCC[C@H]1C(=O)CN1C(=O)C(NC(=O)NC=2C=C(C)C=CC=2)N=C(C=2C=CC=CC=2)C2=CC=CC=C21 VOPNRSWFTFKUAX-QUWDGAPNSA-N 0.000 claims description 4
- INMWFCCMIFVEPO-UHFFFAOYSA-N 1-[3-(dimethylamino)phenyl]-3-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound CN(C)C1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3N=CC=CC=3)=N2)=O)=C1 INMWFCCMIFVEPO-UHFFFAOYSA-N 0.000 claims description 4
- MUMCKBQXVLFNBF-UHFFFAOYSA-N 1-[7-chloro-5-(2-chlorophenyl)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=C(Cl)C=C3C(C=3C(=CC=CC=3)Cl)=N2)=O)=C1 MUMCKBQXVLFNBF-UHFFFAOYSA-N 0.000 claims description 4
- 239000003743 cholecystokinin B receptor antagonist Substances 0.000 claims description 4
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- JZENZFTVQRCUBC-BRIWLPCBSA-N 1-(3-methylphenyl)-3-[2-oxo-1-[2-oxo-2-[(2r)-pyrrolidin-2-yl]ethyl]-5-phenyl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)[C@@H]3NCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 JZENZFTVQRCUBC-BRIWLPCBSA-N 0.000 claims description 3
- YRDCVSLWPXSVMY-UHFFFAOYSA-N 1-[1-(2-cyclobutyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C3CCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 YRDCVSLWPXSVMY-UHFFFAOYSA-N 0.000 claims description 3
- YLGSFAOEFWUIKO-UHFFFAOYSA-N 1-[1-(2-cyclopentyl-2-oxoethyl)-2-oxo-5-pyridin-4-yl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C3CCCC3)C3=CC=CC=C3C(C=3C=CN=CC=3)=N2)=O)=C1 YLGSFAOEFWUIKO-UHFFFAOYSA-N 0.000 claims description 3
- LNHBBGWNSQZZEL-UHFFFAOYSA-N 1-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-nitrophenyl)urea Chemical compound O=C1N(CC(=O)C(C)(C)C)C2=CC=CC=C2C(C=2C=CC=CC=2)=NC1NC(=O)NC1=CC=CC([N+]([O-])=O)=C1 LNHBBGWNSQZZEL-UHFFFAOYSA-N 0.000 claims description 3
- DARHABFSCSRGOG-UHFFFAOYSA-N 3-[[1-(3,3-dimethyl-2-oxopentyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]carbamoylamino]benzoic acid Chemical compound O=C1N(CC(=O)C(C)(C)CC)C2=CC=CC=C2C(C=2C=CC=CC=2)=NC1NC(=O)NC1=CC=CC(C(O)=O)=C1 DARHABFSCSRGOG-UHFFFAOYSA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000000718 duodenal ulcer Diseases 0.000 claims description 3
- 201000000052 gastrinoma Diseases 0.000 claims description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- XBDKUDLNLTTYKW-UHFFFAOYSA-N n-[3-[[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]carbamoylamino]phenyl]formamide Chemical compound O=C1N(CC(=O)C(C)(C)C)C2=CC=CC=C2C(C=2C=CC=CC=2)=NC1NC(=O)NC1=CC=CC(NC=O)=C1 XBDKUDLNLTTYKW-UHFFFAOYSA-N 0.000 claims description 3
- ABJHMASUFPDZRW-DEOSSOPVSA-N 1-(3-aminophenyl)-3-[(3r)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound N([C@@H]1N=C(C2=CC=CC=C2N(C1=O)CC(=O)C(C)(C)C)C=1N=CC=CC=1)C(=O)NC1=CC=CC(N)=C1 ABJHMASUFPDZRW-DEOSSOPVSA-N 0.000 claims description 2
- CNBCNQRFXCKGJF-NDEPHWFRSA-N 1-[(3r)-1-(2-cyclopentyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)N[C@H]2C(N(CC(=O)C3CCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 CNBCNQRFXCKGJF-NDEPHWFRSA-N 0.000 claims description 2
- DVXKDSWTEKGMCH-RSXGOPAZSA-N 1-[(3r)-1-[(2s)-2-hydroxy-3,3-dimethylbutyl]-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)N[C@H]2C(N(C[C@@H](O)C(C)(C)C)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 DVXKDSWTEKGMCH-RSXGOPAZSA-N 0.000 claims description 2
- CNBCNQRFXCKGJF-MUUNZHRXSA-N 1-[(3s)-1-(2-cyclopentyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)N[C@@H]2C(N(CC(=O)C3CCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 CNBCNQRFXCKGJF-MUUNZHRXSA-N 0.000 claims description 2
- IOYYZMHBESBQRA-UHFFFAOYSA-N 1-[1-(2-cycloheptyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C3CCCCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 IOYYZMHBESBQRA-UHFFFAOYSA-N 0.000 claims description 2
- GSTYQWQSRHNRNN-UHFFFAOYSA-N 1-[1-(2-cyclohexyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C3CCCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 GSTYQWQSRHNRNN-UHFFFAOYSA-N 0.000 claims description 2
- IMSUILBIZGRXLR-UHFFFAOYSA-N 1-[1-(2-cyclopentyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methoxyphenyl)urea Chemical compound COC1=CC=CC(NC(=O)NC2C(N(CC(=O)C3CCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 IMSUILBIZGRXLR-UHFFFAOYSA-N 0.000 claims description 2
- TUCVLWXPVRMGPL-UHFFFAOYSA-N 1-[1-(2-cyclopentyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-nitrophenyl)urea Chemical compound [O-][N+](=O)C1=CC=CC(NC(=O)NC2C(N(CC(=O)C3CCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 TUCVLWXPVRMGPL-UHFFFAOYSA-N 0.000 claims description 2
- GNMVNUZRQLYQHI-UHFFFAOYSA-N 1-[1-(2-cyclopentyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-[3-(dimethylamino)phenyl]urea Chemical compound CN(C)C1=CC=CC(NC(=O)NC2C(N(CC(=O)C3CCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 GNMVNUZRQLYQHI-UHFFFAOYSA-N 0.000 claims description 2
- PPWNCSOHCNHQDD-UHFFFAOYSA-N 1-[1-(3-ethyl-2-oxopentyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound O=C1N(CC(=O)C(CC)CC)C2=CC=CC=C2C(C=2C=CC=CC=2)=NC1NC(=O)NC1=CC=CC(C)=C1 PPWNCSOHCNHQDD-UHFFFAOYSA-N 0.000 claims description 2
- YTOIZHIOIUMYEL-UHFFFAOYSA-N 1-[1-(3-methyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound O=C1N(CC(=O)C(C)C)C2=CC=CC=C2C(C=2C=CC=CC=2)=NC1NC(=O)NC1=CC=CC(C)=C1 YTOIZHIOIUMYEL-UHFFFAOYSA-N 0.000 claims description 2
- DZSWOHKLBJAPQM-UHFFFAOYSA-N 3-[[1-(2-cyclopentyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC(=O)NC2C(N(CC(=O)C3CCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 DZSWOHKLBJAPQM-UHFFFAOYSA-N 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 235000021229 appetite regulation Nutrition 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000000468 ketone group Chemical group 0.000 claims description 2
- YDZYKNJZCVIKPP-VWLOTQADSA-N netazepide Chemical compound CNC1=CC=CC(NC(=O)N[C@H]2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3N=CC=CC=3)=N2)=O)=C1 YDZYKNJZCVIKPP-VWLOTQADSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- BCKBRPCMBQSENO-VWLOTQADSA-N 1-(3-aminophenyl)-3-[(3r)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound N([C@@H]1N=C(C2=CC=CC=C2N(C1=O)CC(=O)C(C)(C)C)C=1C=CC=CC=1)C(=O)NC1=CC=CC(N)=C1 BCKBRPCMBQSENO-VWLOTQADSA-N 0.000 claims 1
- BCKBRPCMBQSENO-UHFFFAOYSA-N 1-(3-aminophenyl)-3-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound O=C1N(CC(=O)C(C)(C)C)C2=CC=CC=C2C(C=2C=CC=CC=2)=NC1NC(=O)NC1=CC=CC(N)=C1 BCKBRPCMBQSENO-UHFFFAOYSA-N 0.000 claims 1
- AEFWSJIJISUSSZ-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[1-(2-cycloheptyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound ClC1=CC=CC(NC(=O)NC2C(N(CC(=O)C3CCCCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 AEFWSJIJISUSSZ-UHFFFAOYSA-N 0.000 claims 1
- JZENZFTVQRCUBC-DCCUJTHKSA-N 1-(3-methylphenyl)-3-[2-oxo-1-[2-oxo-2-[(2s)-pyrrolidin-2-yl]ethyl]-5-phenyl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)[C@H]3NCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 JZENZFTVQRCUBC-DCCUJTHKSA-N 0.000 claims 1
- AUPDOGKZFGQZFV-NDEPHWFRSA-N 1-[(3r)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-[3-[ethyl(methyl)amino]phenyl]urea Chemical compound CCN(C)C1=CC=CC(NC(=O)N[C@H]2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 AUPDOGKZFGQZFV-NDEPHWFRSA-N 0.000 claims 1
- MAXKXPNYSHCJHW-UHFFFAOYSA-N 1-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea Chemical compound CNC1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 MAXKXPNYSHCJHW-UHFFFAOYSA-N 0.000 claims 1
- YTVYYUWEMFMKIX-UHFFFAOYSA-N 1-[1-[2-(1-methylcyclopentyl)-2-oxoethyl]-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C3(C)CCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 YTVYYUWEMFMKIX-UHFFFAOYSA-N 0.000 claims 1
- KYWXZMQXYWPUPN-UHFFFAOYSA-N 1-[3-[(dimethylamino)methyl]phenyl]-3-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound CN(C)CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 KYWXZMQXYWPUPN-UHFFFAOYSA-N 0.000 claims 1
- HTUODNDFSPBESN-UHFFFAOYSA-N 1-[5-(2-chlorophenyl)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3C(=CC=CC=3)Cl)=N2)=O)=C1 HTUODNDFSPBESN-UHFFFAOYSA-N 0.000 claims 1
- IIDJGAJSTDDBOY-UHFFFAOYSA-N 1-[7-chloro-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-[3-(dimethylamino)phenyl]urea Chemical compound CN(C)C1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=C(Cl)C=C3C(C=3C=CC=CC=3)=N2)=O)=C1 IIDJGAJSTDDBOY-UHFFFAOYSA-N 0.000 claims 1
- XVHAGPZAHRASFP-UHFFFAOYSA-N C(C)N(C)C1=C(C=CC=C1)NC(N)=O Chemical compound C(C)N(C)C1=C(C=CC=C1)NC(N)=O XVHAGPZAHRASFP-UHFFFAOYSA-N 0.000 claims 1
- 229940123406 CCK B receptor antagonist Drugs 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 102000052874 Gastrin receptors Human genes 0.000 abstract description 3
- 230000008485 antagonism Effects 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 461
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 336
- 235000019439 ethyl acetate Nutrition 0.000 description 229
- 239000003480 eluent Substances 0.000 description 129
- 238000005481 NMR spectroscopy Methods 0.000 description 124
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 108
- 238000000034 method Methods 0.000 description 107
- 238000003818 flash chromatography Methods 0.000 description 102
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 98
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 97
- 229940049706 benzodiazepine Drugs 0.000 description 97
- 239000000741 silica gel Substances 0.000 description 95
- 229910002027 silica gel Inorganic materials 0.000 description 95
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 94
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 94
- 239000007787 solid Substances 0.000 description 89
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- 239000012043 crude product Substances 0.000 description 64
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 62
- 239000000243 solution Substances 0.000 description 58
- 238000004128 high performance liquid chromatography Methods 0.000 description 54
- 239000003208 petroleum Substances 0.000 description 53
- 239000000047 product Substances 0.000 description 52
- 150000002500 ions Chemical class 0.000 description 49
- 239000003921 oil Substances 0.000 description 49
- 235000019198 oils Nutrition 0.000 description 49
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 239000012071 phase Substances 0.000 description 33
- 239000012267 brine Substances 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- 239000000460 chlorine Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 229910001868 water Inorganic materials 0.000 description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- 239000012948 isocyanate Substances 0.000 description 26
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 26
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 25
- 150000002513 isocyanates Chemical class 0.000 description 25
- 239000012312 sodium hydride Substances 0.000 description 25
- 229910000104 sodium hydride Inorganic materials 0.000 description 25
- 239000006185 dispersion Substances 0.000 description 24
- LQQKDSXCDXHLLF-UHFFFAOYSA-N 1,3-dibromopropan-2-one Chemical compound BrCC(=O)CBr LQQKDSXCDXHLLF-UHFFFAOYSA-N 0.000 description 22
- NMPVEAUIHMEAQP-UHFFFAOYSA-N alpha-bromo-acetaldehyde Natural products BrCC=O NMPVEAUIHMEAQP-UHFFFAOYSA-N 0.000 description 22
- XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical class [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 22
- 239000002253 acid Substances 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 150000001412 amines Chemical class 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 16
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 15
- 239000012047 saturated solution Substances 0.000 description 15
- 150000002576 ketones Chemical class 0.000 description 14
- CPPGZWWUPFWALU-UHFFFAOYSA-N 1-isocyanato-3-methylbenzene Chemical compound CC1=CC=CC(N=C=O)=C1 CPPGZWWUPFWALU-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 10
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 108010079943 Pentagastrin Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 8
- 229960000444 pentagastrin Drugs 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- NDNQCTVYOKEYIV-UHFFFAOYSA-N 1h-1,2-benzodiazepin-3-amine Chemical compound C1=CC(N)=NNC2=CC=CC=C21 NDNQCTVYOKEYIV-UHFFFAOYSA-N 0.000 description 5
- 108010089335 Cholecystokinin A Receptor Proteins 0.000 description 5
- 102100034927 Cholecystokinin receptor type A Human genes 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000027119 gastric acid secretion Effects 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 4
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- MXFGREPUAFWYMQ-UHFFFAOYSA-N 1-[3-[(dimethylamino)methyl]phenyl]-3-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound CN(C)CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3N=CC=CC=3)=N2)=O)=C1 MXFGREPUAFWYMQ-UHFFFAOYSA-N 0.000 description 3
- SAIRZMWXVJEBMO-UHFFFAOYSA-N 1-bromo-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CBr SAIRZMWXVJEBMO-UHFFFAOYSA-N 0.000 description 3
- GFFGYTMCNVMFAJ-UHFFFAOYSA-N 1-isocyanato-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(N=C=O)=C1 GFFGYTMCNVMFAJ-UHFFFAOYSA-N 0.000 description 3
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 229910015845 BBr3 Inorganic materials 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- VZFUCHSFHOYXIS-UHFFFAOYSA-N Cycloheptanecarboxylic acid Chemical compound OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- VYWQTJWGWLKBQA-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;chloride Chemical compound Cl.NC(N)=O VYWQTJWGWLKBQA-UHFFFAOYSA-N 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- UVQVMNIYFXZXCI-UHFFFAOYSA-N (3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(N)=O)=C1 UVQVMNIYFXZXCI-UHFFFAOYSA-N 0.000 description 2
- QGOXRTGPIJTFEY-XCZPVHLTSA-N 1-[(3r)-1-[(2r)-2-cyclopentyl-2-hydroxyethyl]-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)N[C@H]2C(N(C[C@H](O)C3CCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 QGOXRTGPIJTFEY-XCZPVHLTSA-N 0.000 description 2
- DCAUPFKGPOSNPW-UHFFFAOYSA-N 1-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methoxyphenyl)urea Chemical compound COC1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 DCAUPFKGPOSNPW-UHFFFAOYSA-N 0.000 description 2
- YDZYKNJZCVIKPP-UHFFFAOYSA-N 1-[1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3h-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea Chemical compound CNC1=CC=CC(NC(=O)NC2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3N=CC=CC=3)=N2)=O)=C1 YDZYKNJZCVIKPP-UHFFFAOYSA-N 0.000 description 2
- GGLPHJZLYBQRAC-UHFFFAOYSA-N 1-[1-(3,3-dimethyl-2-oxopentyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound O=C1N(CC(=O)C(C)(C)CC)C2=CC=CC=C2C(C=2C=CC=CC=2)=NC1NC(=O)NC1=CC=CC(C)=C1 GGLPHJZLYBQRAC-UHFFFAOYSA-N 0.000 description 2
- WHKQPLUIELMQML-UHFFFAOYSA-N 1-[1-[2-(1-methylcyclopropyl)-2-oxoethyl]-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C3(C)CC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 WHKQPLUIELMQML-UHFFFAOYSA-N 0.000 description 2
- NPOVTGVGOBJZPY-UHFFFAOYSA-N 1-isocyanato-3-methoxybenzene Chemical compound COC1=CC=CC(N=C=O)=C1 NPOVTGVGOBJZPY-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- FABVMBDCVAJXMB-UHFFFAOYSA-N 3,5-dichloro-2-hydroxybenzaldehyde Chemical compound OC1=C(Cl)C=C(Cl)C=C1C=O FABVMBDCVAJXMB-UHFFFAOYSA-N 0.000 description 2
- NEGFNJRAUMCZMY-UHFFFAOYSA-N 3-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=CC(C(O)=O)=C1 NEGFNJRAUMCZMY-UHFFFAOYSA-N 0.000 description 2
- NMVMMIVEFVPTRF-GPNIZQGCSA-N 3-[[(3r)-1-(2-cyclopentyl-2-hydroxyethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]carbamoylamino]benzoic acid Chemical compound N([C@@H]1N=C(C2=CC=CC=C2N(C1=O)CC(O)C1CCCC1)C=1C=CC=CC=1)C(=O)NC1=CC=CC(C(O)=O)=C1 NMVMMIVEFVPTRF-GPNIZQGCSA-N 0.000 description 2
- GYLKKXHEIIFTJH-UHFFFAOYSA-N 3-cyanobenzoic acid Chemical compound OC(=O)C1=CC=CC(C#N)=C1 GYLKKXHEIIFTJH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- YVHAIVPPUIZFBA-UHFFFAOYSA-N Cyclopentylacetic acid Chemical compound OC(=O)CC1CCCC1 YVHAIVPPUIZFBA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical compound COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- VZDNXXPBYLGWOS-UHFFFAOYSA-N methyl 3-aminobenzoate Chemical compound COC(=O)C1=CC=CC(N)=C1 VZDNXXPBYLGWOS-UHFFFAOYSA-N 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- ZQEBQGAAWMOMAI-SSDOTTSWSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(O)=O ZQEBQGAAWMOMAI-SSDOTTSWSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- QHFKWIKCUHNXAU-UHFFFAOYSA-N (4-nitrophenyl) carbamate Chemical compound NC(=O)OC1=CC=C([N+]([O-])=O)C=C1 QHFKWIKCUHNXAU-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DXMNJSHCPPFVHG-UHFFFAOYSA-N (hydroxyamino) nitroformate Chemical compound ONOC(=O)[N+]([O-])=O DXMNJSHCPPFVHG-UHFFFAOYSA-N 0.000 description 1
- ZVJUTDORASFVHU-UHFFFAOYSA-N 1,3-bis(1-adamantyl)-1,3-dibromopropan-2-one Chemical compound C1C(C2)CC(C3)CC2CC13C(Br)C(=O)C(Br)C1(C2)CC(C3)CC2CC3C1 ZVJUTDORASFVHU-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- OQBCJXUAQQMTRW-UHFFFAOYSA-N 1-(1-methylcyclopropyl)ethanone Chemical compound CC(=O)C1(C)CC1 OQBCJXUAQQMTRW-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- OCWLXZANZZFWCX-VWLOTQADSA-N 1-[(3r)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)N[C@H]2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3N=CC=CC=3)=N2)=O)=C1 OCWLXZANZZFWCX-VWLOTQADSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- CNBCNQRFXCKGJF-UHFFFAOYSA-N 1-[1-(2-cyclopentyl-2-oxoethyl)-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC2C(N(CC(=O)C3CCCC3)C3=CC=CC=C3C(C=3C=CC=CC=3)=N2)=O)=C1 CNBCNQRFXCKGJF-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- INMWFCCMIFVEPO-SANMLTNESA-N 1-[3-(dimethylamino)phenyl]-3-[(3r)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound CN(C)C1=CC=CC(NC(=O)N[C@H]2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3N=CC=CC=3)=N2)=O)=C1 INMWFCCMIFVEPO-SANMLTNESA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- YQNZIAZUQRMAAH-UHFFFAOYSA-N 1-bromo-3-cyclohexylpropan-2-one Chemical compound BrCC(=O)CC1CCCCC1 YQNZIAZUQRMAAH-UHFFFAOYSA-N 0.000 description 1
- HHIRBXHEYVDUAM-UHFFFAOYSA-N 1-chloro-3-isocyanatobenzene Chemical compound ClC1=CC=CC(N=C=O)=C1 HHIRBXHEYVDUAM-UHFFFAOYSA-N 0.000 description 1
- REHQLKUNRPCYEW-UHFFFAOYSA-N 1-methylcyclohexane-1-carboxylic acid Chemical compound OC(=O)C1(C)CCCCC1 REHQLKUNRPCYEW-UHFFFAOYSA-N 0.000 description 1
- VUAXHMVRKOTJKP-UHFFFAOYSA-N 2,2-dimethylbutyric acid Chemical compound CCC(C)(C)C(O)=O VUAXHMVRKOTJKP-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- XUSKZLBLGHBCLD-UHFFFAOYSA-N 2-(3-aminophenyl)acetic acid Chemical compound NC1=CC=CC(CC(O)=O)=C1 XUSKZLBLGHBCLD-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NJHBEJLMTNLOSL-UHFFFAOYSA-N 2-bromo-1-(1-methylcyclopentyl)ethanone Chemical compound BrCC(=O)C1(C)CCCC1 NJHBEJLMTNLOSL-UHFFFAOYSA-N 0.000 description 1
- VCUXURBVRXWSQQ-UHFFFAOYSA-N 2-bromo-1-(1-methylcyclopropyl)ethanone Chemical compound BrCC(=O)C1(C)CC1 VCUXURBVRXWSQQ-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- ZVRPYPOCLYAYKL-UHFFFAOYSA-N 3,5-bis(diazomethyl)-3,5-diethylheptan-4-one Chemical compound [N+](=[N-])=CC(CC)(CC)C(=O)C(C=[N+]=[N-])(CC)CC ZVRPYPOCLYAYKL-UHFFFAOYSA-N 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- FNCRWFSUYPEDSM-UHFFFAOYSA-N 3-(diethylamino)benzoic acid Chemical compound CCN(CC)C1=CC=CC(C(O)=O)=C1 FNCRWFSUYPEDSM-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- JOHOBHQNCZAHOU-UHFFFAOYSA-N 3-[(dimethylamino)methyl]benzoic acid Chemical compound CN(C)CC1=CC=CC(C(O)=O)=C1 JOHOBHQNCZAHOU-UHFFFAOYSA-N 0.000 description 1
- CWBMFVGIEVNOTQ-UHFFFAOYSA-N 3-[(dimethylamino)methyl]benzonitrile Chemical compound CN(C)CC1=CC=CC(C#N)=C1 CWBMFVGIEVNOTQ-UHFFFAOYSA-N 0.000 description 1
- JLVWHNLHQAKXTG-UHFFFAOYSA-N 3-[ethyl(methyl)amino]benzoic acid Chemical compound CCN(C)C1=CC=CC(C(O)=O)=C1 JLVWHNLHQAKXTG-UHFFFAOYSA-N 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- YLPTWUHNZZZVEX-UHFFFAOYSA-N 3-formamidobenzoic acid Chemical compound OC(=O)C1=CC=CC(NC=O)=C1 YLPTWUHNZZZVEX-UHFFFAOYSA-N 0.000 description 1
- HGZJJKZPPMFIBU-UHFFFAOYSA-N 3-formylbenzonitrile Chemical compound O=CC1=CC=CC(C#N)=C1 HGZJJKZPPMFIBU-UHFFFAOYSA-N 0.000 description 1
- WMZNGTSLFSJHMZ-UHFFFAOYSA-N 3-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=CC(C(O)=O)=C1 WMZNGTSLFSJHMZ-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- BQRJQAACCPRZPK-UHFFFAOYSA-N 5-thiophen-2-yl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound N=1C2=C(C(=O)O)C=NN2C(C(F)(F)F)=CC=1C1=CC=CS1 BQRJQAACCPRZPK-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- QUXLCYFNVNNRBE-UHFFFAOYSA-N 6-methylpyridin-2-amine Chemical compound CC1=CC=CC(N)=N1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100028628 Bombesin receptor subtype-3 Human genes 0.000 description 1
- HKQYGQJAKULNNH-UHFFFAOYSA-N BrCC(CC)(CC)C(=O)C(CBr)(CC)CC Chemical compound BrCC(CC)(CC)C(=O)C(CBr)(CC)CC HKQYGQJAKULNNH-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 101710150887 Cholecystokinin A Proteins 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000695054 Homo sapiens Bombesin receptor subtype-3 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- MIBQYWIOHFTKHD-UHFFFAOYSA-N adamantane-1-carbonyl chloride Chemical compound C1C(C2)CC3CC2CC1(C(=O)Cl)C3 MIBQYWIOHFTKHD-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- ZFRMIHHMFIRJQD-UHFFFAOYSA-N benzyl n-(2-oxo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-3-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(C(NC1=CC=CC=C11)=O)N=C1C1=CC=CC=N1 ZFRMIHHMFIRJQD-UHFFFAOYSA-N 0.000 description 1
- BCWAHKPBTCRRDC-UHFFFAOYSA-N benzyl n-(2-oxo-5-pyridin-4-yl-1,3-dihydro-1,4-benzodiazepin-3-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(C(NC1=CC=CC=C11)=O)N=C1C1=CC=NC=C1 BCWAHKPBTCRRDC-UHFFFAOYSA-N 0.000 description 1
- JZQHSKKXGOVQPA-UHFFFAOYSA-N benzyl n-(7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)carbamate Chemical compound N1=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2NC(=O)C1NC(=O)OCC1=CC=CC=C1 JZQHSKKXGOVQPA-UHFFFAOYSA-N 0.000 description 1
- NWNUWXGDMFPMGQ-UHFFFAOYSA-N benzyl n-(8-methyl-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)carbamate Chemical compound C=1C(C)=CC=C(C(=N2)C=3C=CC=CC=3)C=1NC(=O)C2NC(=O)OCC1=CC=CC=C1 NWNUWXGDMFPMGQ-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- KFYFKXVSOIZYRN-UHFFFAOYSA-N benzyl n-[5-(4-methylphenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound C1=CC(C)=CC=C1C(C1=CC=CC=C1NC1=O)=NC1NC(=O)OCC1=CC=CC=C1 KFYFKXVSOIZYRN-UHFFFAOYSA-N 0.000 description 1
- FMPXLSZJACGNOR-UHFFFAOYSA-N benzyl n-[7-chloro-5-(2-chlorophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound N1=C(C=2C(=CC=CC=2)Cl)C2=CC(Cl)=CC=C2NC(=O)C1NC(=O)OCC1=CC=CC=C1 FMPXLSZJACGNOR-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- VNGOYPQMJFJDLV-UHFFFAOYSA-N dimethyl benzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC=CC(C(=O)OC)=C1 VNGOYPQMJFJDLV-UHFFFAOYSA-N 0.000 description 1
- DASKKRDHXATCCX-UHFFFAOYSA-N ethyl 3-(diethylamino)benzoate Chemical compound CCOC(=O)C1=CC=CC(N(CC)CC)=C1 DASKKRDHXATCCX-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- BVKGNQRDVFGNIW-UHFFFAOYSA-N methyl 2-(3-aminophenyl)acetate Chemical compound COC(=O)CC1=CC=CC(N)=C1 BVKGNQRDVFGNIW-UHFFFAOYSA-N 0.000 description 1
- WITYUUTUSPKOAB-UHFFFAOYSA-N methyl 2-methyl-2-phenylpropanoate Chemical compound COC(=O)C(C)(C)C1=CC=CC=C1 WITYUUTUSPKOAB-UHFFFAOYSA-N 0.000 description 1
- ZQITUIHFLCKDMR-UHFFFAOYSA-N methyl 3-[ethyl(methyl)amino]benzoate Chemical compound CCN(C)C1=CC=CC(C(=O)OC)=C1 ZQITUIHFLCKDMR-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YTZKOQUCBOVLHL-UHFFFAOYSA-N tert-butylbenzene Chemical compound CC(C)(C)C1=CC=CC=C1 YTZKOQUCBOVLHL-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N trimethylmethane Natural products CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9204221A GB2264492B (en) | 1992-02-27 | 1992-02-27 | Benzodiazepine derivatives |
GB929212740A GB9212740D0 (en) | 1992-02-27 | 1992-06-16 | Benzodiazephine derivatives |
PCT/GB1993/000404 WO1993016999A1 (en) | 1992-02-27 | 1993-02-26 | Benzodiazepin derivatives useful as cck-receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
NO943133L NO943133L (no) | 1994-08-24 |
NO943133D0 NO943133D0 (no) | 1994-08-24 |
NO311215B1 true NO311215B1 (no) | 2001-10-29 |
Family
ID=26300386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19943133A NO311215B1 (no) | 1992-02-27 | 1994-08-24 | Benzodiazepinderivater egnet til bruk som CCK- reseptorantagonister |
Country Status (18)
Country | Link |
---|---|
US (2) | US5688943A (ru) |
EP (1) | EP0628033B1 (ru) |
JP (1) | JP2571344B2 (ru) |
CN (1) | CN1051079C (ru) |
AT (1) | ATE245632T1 (ru) |
AU (1) | AU672390B2 (ru) |
CA (1) | CA2129990C (ru) |
DE (1) | DE69333108T2 (ru) |
DK (1) | DK0628033T3 (ru) |
ES (1) | ES2203616T3 (ru) |
FI (1) | FI121234B (ru) |
HU (1) | HU224012B1 (ru) |
IL (1) | IL104853A (ru) |
NO (1) | NO311215B1 (ru) |
PT (1) | PT628033E (ru) |
RU (1) | RU2139282C1 (ru) |
TW (1) | TW438783B (ru) |
WO (1) | WO1993016999A1 (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2119875A1 (en) * | 1991-10-24 | 1993-04-29 | Sylvie Bourrain | Benzodiazepine derivatives, compositions containing them and their use in therapy |
GB2282594A (en) * | 1993-08-25 | 1995-04-12 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives |
GB2282595A (en) * | 1993-08-25 | 1995-04-12 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives |
US5556969A (en) * | 1994-12-07 | 1996-09-17 | Merck Sharp & Dohme Ltd. | Benzodiazepine derivatives |
AUPO284396A0 (en) * | 1996-10-08 | 1996-10-31 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
US6100254A (en) * | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
US20040138207A1 (en) * | 2001-05-11 | 2004-07-15 | Mayumi Yamano | Antitumor agents |
US7524837B2 (en) | 2003-05-12 | 2009-04-28 | Janssen Pharmaceutica N.V. | Benzotriazapinone salts and methods for using same |
JP5197361B2 (ja) * | 2005-06-06 | 2013-05-15 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | 睡眠障害を処置するための組成物および方法 |
CN101669557B (zh) * | 2009-08-20 | 2012-07-25 | 杭州六易科技有限公司 | 一种清热解毒凉茶的制作方法 |
WO2011037128A1 (ja) | 2009-09-28 | 2011-03-31 | 日本曹達株式会社 | 含窒素ヘテロ環化合物およびその塩ならびに農園芸用殺菌剤 |
RU2693484C1 (ru) | 2013-11-22 | 2019-07-03 | СиЭль БАЙОСАЕНСИЗ ЭлЭлСи | Антагонисты гастрина для лечения и профилактики остеопороза |
GB201414116D0 (en) | 2014-08-08 | 2014-09-24 | Trio Medicines Ltd | Benzodiazepine derivatives |
GB201513979D0 (en) | 2015-08-07 | 2015-09-23 | Trio Medicines Ltd | Synthesis of benzodiazepine derivatives |
WO2018049129A1 (en) * | 2016-09-09 | 2018-03-15 | On Target Laboratories, LLC | Cholecystokinin 2 receptor targeted nir imaging and use thereof |
US10881667B2 (en) * | 2018-10-30 | 2021-01-05 | City University Of Hong Kong | Method and composition for treating epilepsy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4820834A (en) * | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
CA2026856A1 (en) * | 1989-10-05 | 1991-04-06 | Mark G. Bock | 3-substituted-1,4-benzodiazepines useful as oxytocin |
CA2032226A1 (en) * | 1989-12-18 | 1991-06-19 | Mark G. Bock | Benzodiazepine analogs |
IE904560A1 (en) * | 1989-12-18 | 1991-06-19 | Merck & Co Inc | New benzodiazepine analogs |
IL96613A0 (en) * | 1989-12-18 | 1991-09-16 | Merck & Co Inc | Pharmaceutical compositions containing benzodiazepine analogs |
US4994258A (en) * | 1990-03-05 | 1991-02-19 | Merck & Co., Inc. | Gamma emitting, CCK-A antagonists for pancreatic imaging |
US5206234A (en) * | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
US5218114A (en) * | 1991-04-10 | 1993-06-08 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5218115A (en) * | 1991-04-10 | 1993-06-08 | Merck & Co., Inc. | Cholecystokinin antagonists |
-
1993
- 1993-02-25 IL IL104853A patent/IL104853A/xx not_active IP Right Cessation
- 1993-02-26 AT AT93905480T patent/ATE245632T1/de not_active IP Right Cessation
- 1993-02-26 US US08/284,462 patent/US5688943A/en not_active Expired - Lifetime
- 1993-02-26 WO PCT/GB1993/000404 patent/WO1993016999A1/en active IP Right Grant
- 1993-02-26 DK DK93905480T patent/DK0628033T3/da active
- 1993-02-26 ES ES93905480T patent/ES2203616T3/es not_active Expired - Lifetime
- 1993-02-26 PT PT93905480T patent/PT628033E/pt unknown
- 1993-02-26 RU RU94038255A patent/RU2139282C1/ru active
- 1993-02-26 DE DE69333108T patent/DE69333108T2/de not_active Expired - Fee Related
- 1993-02-26 EP EP93905480A patent/EP0628033B1/en not_active Expired - Lifetime
- 1993-02-26 JP JP5506433A patent/JP2571344B2/ja not_active Expired - Lifetime
- 1993-02-26 AU AU36391/93A patent/AU672390B2/en not_active Expired
- 1993-02-26 CA CA002129990A patent/CA2129990C/en not_active Expired - Lifetime
- 1993-02-26 HU HU9402212A patent/HU224012B1/hu active IP Right Grant
- 1993-02-27 CN CN93101848A patent/CN1051079C/zh not_active Expired - Lifetime
- 1993-03-24 TW TW082102213A patent/TW438783B/zh not_active IP Right Cessation
-
1994
- 1994-08-24 NO NO19943133A patent/NO311215B1/no not_active IP Right Cessation
- 1994-08-26 FI FI943941A patent/FI121234B/fi not_active IP Right Cessation
-
1997
- 1997-06-06 US US08/867,422 patent/US5962451A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
NO943133L (no) | 1994-08-24 |
JP2571344B2 (ja) | 1997-01-16 |
HUT67963A (en) | 1995-05-29 |
FI121234B (fi) | 2010-08-31 |
CN1075717A (zh) | 1993-09-01 |
RU94038255A (ru) | 1996-07-10 |
AU672390B2 (en) | 1996-10-03 |
AU3639193A (en) | 1993-09-13 |
US5688943A (en) | 1997-11-18 |
DE69333108T2 (de) | 2004-04-15 |
HU224012B1 (hu) | 2005-04-28 |
TW438783B (en) | 2001-06-07 |
ES2203616T3 (es) | 2004-04-16 |
FI943941A (fi) | 1994-10-26 |
JPH07505121A (ja) | 1995-06-08 |
WO1993016999A1 (en) | 1993-09-02 |
PT628033E (pt) | 2003-12-31 |
RU2139282C1 (ru) | 1999-10-10 |
EP0628033B1 (en) | 2003-07-23 |
CA2129990A1 (en) | 1993-09-02 |
DK0628033T3 (da) | 2003-11-10 |
EP0628033A1 (en) | 1994-12-14 |
ATE245632T1 (de) | 2003-08-15 |
CA2129990C (en) | 2006-01-10 |
NO943133D0 (no) | 1994-08-24 |
CN1051079C (zh) | 2000-04-05 |
IL104853A (en) | 1997-11-20 |
DE69333108D1 (de) | 2003-08-28 |
HU9402212D0 (en) | 1994-09-28 |
FI943941A0 (fi) | 1994-08-26 |
IL104853A0 (en) | 1993-06-10 |
US5962451A (en) | 1999-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3999819B2 (ja) | 1,5―ベンゾジアセピン誘導体 | |
NO311215B1 (no) | Benzodiazepinderivater egnet til bruk som CCK- reseptorantagonister | |
EP0636123A1 (en) | 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy | |
CA2541470C (en) | Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors | |
EP1313426A2 (en) | Succinoylamino benzodiazepines as inhibitors of a-beta protein production | |
JPH05178843A (ja) | ベンゾジアゼピン誘導体、それらを含有した組成物及びそれらの治療に関する用途 | |
EP0715624B1 (en) | Process for the preparation of benzodiazepine compounds useful as antagonists of cck or of gastrine | |
US5521175A (en) | Benzodiazepine derivatives | |
WO1994000438A1 (en) | Novel benzodiazepine derivative | |
LV12314B (en) | HOLECISTOKININ ANTAGONISTS | |
ES2364637T3 (es) | Derivados de benzodiazepina útiles como antagonistas de receptores cck. | |
WO1995006041A1 (en) | 3-phenylureido-1,4-benzodiazepines useful as selective cck-b antagonists | |
JP2726158B2 (ja) | 新規ベンゾジアゼピン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |